Abstract | BACKGROUND: PATIENTS AND METHODS: RESULTS: In this study, 106 patients received treatment: 62 patients in the AR stratum and 44 patients in the ATR stratum. The objective tumour response rate in the intent-to-treat population was 18% (95% confidence intervals (CI): 11%-27%), including three complete responses. The response rate was similar in both strata: 19% in the AR and 16% in the ATR stratum. The overall median duration of response was 23.6 weeks. The treatment was well tolerated with a low incidence of grade 3 or 4 toxicities that were considered attributable to study medication. CONCLUSION: Treatment with oral eniluracil- fluorouracil was well tolerated by patients with advanced breast cancer. The efficacy data were comparable with those of other published studies in this group of refractory patients.
|
Authors | T Skovsgaard, N G Davidson, M J Piccart, D J Richel, J Bonneterre, D T Cirkel, C M Barton, Eniluracil/Fluorouracil Breast Cancer Study Group |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 12
Issue 9
Pg. 1255-7
(Sep 2001)
ISSN: 0923-7534 [Print] England |
PMID | 11697836
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibiotics, Antineoplastic
- Bridged-Ring Compounds
- Taxoids
- taxane
- eniluracil
- Uracil
- Fluorouracil
|
Topics |
- Administration, Oral
- Adult
- Aged
- Antibiotics, Antineoplastic
(pharmacology)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, therapeutic use)
- Breast Neoplasms
(drug therapy, pathology)
- Bridged-Ring Compounds
(pharmacology)
- Drug Resistance, Neoplasm
- Female
- Fluorouracil
(administration & dosage)
- Humans
- Middle Aged
- Taxoids
- Treatment Outcome
- Uracil
(administration & dosage, analogs & derivatives)
|